Cetuximab as salvage therapy in 82 year old women with metastatic colon cancer

被引：0

作者：

Krzemieniecki, Krzysztof ^{[1
]}

机构：

[1] Uniwersytetu Med Krakowie, Coll Med, Klin Onkol, Ul Sniadeckich 10, PL-31531 Krakow, Poland

来源：

ONCOLOGY IN CLINICAL PRACTICE | 2012年 / 8卷 / 02期

关键词：

metastatic colon cancer; elderly patients; cetuximab;

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Anticancer treatment offered to elderly requests basic knowledge on geriatric problems and understanding the limits related to reduced functional reserves. Cetuximab was prescribed as the rescue monotherapy to 82 years old women with metastatic colon cancer following failure of systemic treatment. The decrease in bothersome disease symptoms and temporary remission of metastatic lesions revealed in the imaging assessment were observed during treatment. Patient survived additional 10 months. Treatment was well tolerated and toxicity was easy manageable. Monotherapy with cetuximab can be a valuable palliative option in the adequately selected patients.

引用

页码：65 / 66

页数：2

共 50 条

[1] Predictive factors for the efficacy of cetuximab plus chemotherapy as salvage therapy in metastatic gastric cancer patients
Park, Sook Ryun
Kook, Myeong-Cherl
Choi, Il Ju
Kim, Chan Gyoo
Lee, Jong Yeul
Cho, Soo-Jeong
Kim, Young-Woo
Ryu, Keun Won
Lee, Jun Ho
Lee, Jong Seok
Park, Young-Iee
Kim, Noe Kyeong
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2010, 65 (03) : 579 - 587
[2] Predictive factors for the efficacy of cetuximab plus chemotherapy as salvage therapy in metastatic gastric cancer patients
Sook Ryun Park
Myeong-Cherl Kook
Il Ju Choi
Chan Gyoo Kim
Jong Yeul Lee
Soo-Jeong Cho
Young-Woo Kim
Keun Won Ryu
Jun Ho Lee
Jong Seok Lee
Young-Iee Park
Noe Kyeong Kim
Cancer Chemotherapy and Pharmacology, 2010, 65 : 579 - 587
[3] Efficacy of Cetuximab in Metastatic Colon Cancer - Case Report
Grigorean, V. T.
Ciuhu, A. N.
Nita, G. Rahnea
Strambu, V.
Straja, D. N.
Popescu, M.
Sandu, A. M.
Nita, R. A. Rahnea
CHIRURGIA, 2014, 109 (03) : 383 - 389
[4] Metastatic Colon Cancer in an 18-Year-Old without Predisposing Factors
Mirchandani, Divya
Kulpa, Jolanta
Khawar, Nayaab
Kochin, Israel
Narula, Pramod
Sundaram, Revathy
CASE REPORTS IN PEDIATRICS, 2016, 2016
[5] Pharmacogenomic analysis of the triplet combination of gemcitabine, oxaliplatin, and cetuximab as salvage therapy for metastatic colorectal cancer (mCRC) patients
Hernandez, A.
Bandres, E.
Rodriguez, J.
Bitarte, N.
Ramirez, N.
Zarate, R.
Abajo, A.
Chopitea, A.
Viudez, A.
Garcia-Foncillas, J.
JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
[6] Pharmacogenomic analysis of the triplet combination of gemcitabine, oxaliplatin and cetuximab as salvage therapy for metastatic colorectal cancer (mCRC) patients
Bandres, E.
Rodriguez, J.
Hernandez, A.
Bitarte, N.
Ramirez, N.
Diaz-Gonzalez, J. A.
Chopitea, A.
Ponz, M.
Zarate, R. N.
Garcia-Foncillas, J.
EJC SUPPLEMENTS, 2009, 7 (02): : 113 - 113
[7] Raltitrexed as salvage therapy for metastatic colorectal cancer
Ismael, Ghanem
Juan Luis, Torres-Tenor
Oliver, Higuera
Nuria, Rodriguez
Ana, Custodio
Virginia, Martinez-Marin
Angela, Santiago
Tania, Garcia-Pena
Alejandro, Gallego
Jaime, Feliu
ANNALS OF ONCOLOGY, 2017, 28
[8] Therapy with cetuximab and irinotecan in refractory metastatic colorectal cancer
Nature Clinical Practice Oncology, 2008, 5 (9): : 497 - 498
[9] Targeted therapy in metastatic colon cancer
Bhatt, Vijaya R.
FUTURE ONCOLOGY, 2014, 10 (05) : 707 - 711
[10] Addition of bevacizumab or sunitinib to biweekly cetuximab and irinotecan as salvage therapy in patients with metastatic colorectal cancer after failure to CetIri
Pfeiffer, P.
Joergensen, T. L.
Jensen, B. V.
Qvortrup, C.
Skougaard, K.
Bjerregaard, J. K.
Hansen, T. P.
Hogdal, E.
Nielsen, D.
JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)

← 1 2 3 4 5 →